{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:27Z","timestamp":1790742027889,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"23","funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1U01CA214411"],"award-info":[{"award-number":["1U01CA214411"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["122854-PF-12-226-01-CDD"],"award-info":[{"award-number":["122854-PF-12-226-01-CDD"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Drug-induced resistance, or tolerance, is an emerging yet poorly understood failure of anticancer therapy. The interplay between drug-tolerant cancer cells and innate immunity within the tumor, the consequence on tumor growth, and therapeutic strategies to address these challenges remain undescribed. Here, we elucidate the role of taxane-induced resistance on natural killer (NK) cell tumor immunity in triple-negative breast cancer (TNBC) and the design of spatiotemporally controlled nanomedicines, which boost therapeutic efficacy and invigorate \u201cdisabled\u201d NK cells. Drug tolerance limited NK cell immune surveillance via drug-induced depletion of the NK-activating ligand receptor axis, NK group 2 member D, and MHC class I polypeptide-related sequence A, B. Systems biology supported by empirical evidence revealed the heat shock protein 90 (Hsp90) simultaneously controls immune surveillance and persistence of drug-treated tumor cells. On the basis of this evidence, we engineered a \u201cchimeric\u201d nanotherapeutic tool comprising taxanes and a cholesterol-tethered Hsp90 inhibitor, radicicol, which targets the tumor, reduces tolerance, and optimally reprimes NK cells via prolonged induction of NK-activating ligand receptors via temporal control of drug release in vitro and in vivo. A human ex vivo TNBC model confirmed the importance of NK cells in drug-induced death under pressure of clinically approved agents. These findings highlight a convergence between drug-induced resistance, the tumor immune contexture, and engineered approaches that consider the tumor and microenvironment to improve the success of combinatorial therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study uncovers a molecular mechanism linking drug-induced resistance and tumor immunity and provides novel engineered solutions that target these mechanisms in the tumor and improve immunity, thus mitigating off-target effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/0008-5472.can-19-4036","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T15:05:11Z","timestamp":1603119911000},"page":"5355-5366","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nanoengineered Disruption of Heat Shock Protein 90 Targets Drug-Induced Resistance and Relieves Natural Killer Cell Suppression in Breast Cancer"],"prefix":"10.1158","volume":"80","author":[{"given":"Munisha","family":"Smalley","sequence":"first","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva Kumar","family":"Natarajan","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanta","family":"Mondal","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Best","sequence":"additional","affiliation":[{"name":"2Integrative Immuno-Oncology Center, Farcast Biosciences, Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Goldman","sequence":"additional","affiliation":[{"name":"37730 Blackcrest Pl, Tucson, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basavaraja","family":"Shanthappa","sequence":"additional","affiliation":[{"name":"2Integrative Immuno-Oncology Center, Farcast Biosciences, Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0014-5379","authenticated-orcid":false,"given":"Moriah","family":"Pellowe","sequence":"additional","affiliation":[{"name":"4Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2677-603X","authenticated-orcid":false,"given":"Chinmayee","family":"Dash","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanmoy","family":"Saha","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Khiste","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nithya","family":"Ramadurai","sequence":"additional","affiliation":[{"name":"2Integrative Immuno-Oncology Center, Farcast Biosciences, Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8980-9310","authenticated-orcid":false,"given":"Elliot O.","family":"Eton","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Smalley","sequence":"additional","affiliation":[{"name":"5Tufts Medical School, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Brown","sequence":"additional","affiliation":[{"name":"6Division of Computational Genomics, Arrayo, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen","family":"Thayakumar","sequence":"additional","affiliation":[{"name":"2Integrative Immuno-Oncology Center, Farcast Biosciences, Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamunur","family":"Rahman","sequence":"additional","affiliation":[{"name":"7Medical and Biological Laboratories International, Woburn, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Arai","sequence":"additional","affiliation":[{"name":"8JSR Life Sciences, Minato-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Kohandel","sequence":"additional","affiliation":[{"name":"4Department of Applied Mathematics, University of Waterloo, Waterloo, Ontario, Canada."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiladitya","family":"Sengupta","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Goldman","sequence":"additional","affiliation":[{"name":"1Division of Engineering in Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2020,12,2]]},"reference":[{"key":"2022061706334226500_bib1","doi-asserted-by":"crossref","first-page":"439","DOI":"10.3322\/caac.21412","article-title":"Breast cancer statistics, 2017, racial disparity in mortality by state","volume":"67","author":"DeSantis","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"2022061706334226500_bib2","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061706334226500_bib3","first-page":"93","article-title":"Triple-negative breast cancer: treatment challenges and solutions","volume":"8","author":"Collignon","year":"2016","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"2022061706334226500_bib4","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-010-1293-1","article-title":"Triple negative breast cancer: unmet medical needs","volume":"125","author":"Pal","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2022061706334226500_bib5","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.18632\/oncotarget.12284","article-title":"Triple-negative breast cancer: is there a treatment on the horizon?","volume":"8","author":"Yao","year":"2017","journal-title":"Oncotarget"},{"key":"2022061706334226500_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrd.2017.163","article-title":"Cancer immunotherapy: searching in the immune checkpoint black box","volume":"16","author":"Villanueva","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706334226500_bib7","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/cncr.31272","article-title":"Checkpoint inhibitors in triple-negative breast cancer (TNBC): where to go from here","volume":"124","author":"Kwa","year":"2018","journal-title":"Cancer"},{"key":"2022061706334226500_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s12032-017-1071-6","article-title":"Immunotherapy in triple-negative breast cancer","volume":"35","author":"Katz","year":"2017","journal-title":"Med Oncol"},{"key":"2022061706334226500_bib9","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"2022061706334226500_bib10","doi-asserted-by":"crossref","first-page":"5138","DOI":"10.2741\/3070","article-title":"Resistance mechanisms to cancer chemotherapy","volume":"13","author":"Redmond","year":"2008","journal-title":"Front Biosci"},{"key":"2022061706334226500_bib11","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/bjc.2015.146","article-title":"Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: \u2018what does not kill me strengthens me\u2019","volume":"112","author":"Pisco","year":"2015","journal-title":"Br J Cancer"},{"key":"2022061706334226500_bib12","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1038\/ncomms7139","article-title":"Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition","volume":"6","author":"Goldman","year":"2015","journal-title":"Nat Commun"},{"key":"2022061706334226500_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.cell.2004.12.024","article-title":"Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone","volume":"120","author":"Zhao","year":"2005","journal-title":"Cell"},{"key":"2022061706334226500_bib14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.bcp.2011.11.011","article-title":"Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs","volume":"83","author":"Lu","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"2022061706334226500_bib15","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706334226500_bib16","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3892\/mco.2016.963","article-title":"Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials","volume":"5","author":"Wang","year":"2016","journal-title":"Mol Clin Oncol"},{"key":"2022061706334226500_bib17","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"2022061706334226500_bib18","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat Immunol"},{"key":"2022061706334226500_bib19","doi-asserted-by":"crossref","first-page":"a026583","DOI":"10.1101\/cshperspect.a026583","article-title":"Spatial heterogeneity in the tumor microenvironment","volume":"6","author":"Yuan","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2022061706334226500_bib20","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s40425-019-0667-0","article-title":"Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape","volume":"7","author":"Osipov","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2022061706334226500_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41568-019-0193-x","article-title":"CD24 - a novel \u2018don't eat me\u2019 signal","volume":"19","author":"Bradley","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2022061706334226500_bib22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1126\/science.279.5357.1737","article-title":"Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells","volume":"279","author":"Groh","year":"1998","journal-title":"Science"},{"key":"2022061706334226500_bib23","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"2022061706334226500_bib24","doi-asserted-by":"crossref","first-page":"101229","DOI":"10.1016\/j.isci.2020.101229","article-title":"Integrating systems biology and an ex vivo human tumor model elucidates PD-1 blockade response dynamics","volume":"23","author":"Smalley","year":"2020","journal-title":"iScience"},{"key":"2022061706334226500_bib25","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1038\/ncomms7169","article-title":"Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity","volume":"6","author":"Majumder","year":"2015","journal-title":"Nat Commun"},{"key":"2022061706334226500_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/sajc.sajc_118_18","article-title":"Practical consensus recommendations on management of triple-negative metastatic breast cancer","volume":"7","author":"Rangarao","year":"2018","journal-title":"South Asian J Cancer"},{"key":"2022061706334226500_bib27","doi-asserted-by":"crossref","first-page":"e0162394","DOI":"10.1371\/journal.pone.0162394","article-title":"A novel high-throughput 3D screening system for EMT inhibitors: a pilot screening discovered the EMT inhibitory activity of CDK2 inhibitor SU9516","volume":"11","author":"Arai","year":"2016","journal-title":"PLoS One"},{"key":"2022061706334226500_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1126\/science.285.5428.727","article-title":"Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA","volume":"285","author":"Bauer","year":"1999","journal-title":"Science"},{"key":"2022061706334226500_bib29","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V76.8.1580.1580","article-title":"Effect of recombinant human granulocyte-macrophage colony-stimulating factor administration on the lymphocyte subsets of patients with refractory aplastic anemia","volume":"76","author":"Faisal","year":"1990","journal-title":"Blood"},{"key":"2022061706334226500_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1537-2995.2010.02820.x","article-title":"Granulocyte-colony-stimulatory factor: a strong inhibitor of natural killer cell function","volume":"51","author":"Schlahsa","year":"2011","journal-title":"Transfusion"},{"key":"2022061706334226500_bib31","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/02656736.2013.821526","article-title":"Enhanced sensitivity of colon tumour cells to natural killer cell cytotoxicity after mild thermal stress is regulated through HSF1-mediated expression of MICA","volume":"29","author":"Dayanc","year":"2013","journal-title":"Int J Hyperthermia"},{"key":"2022061706334226500_bib32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2091-6-4","article-title":"Analysis of phosphorylation of human heat shock factor 1 in cells experiencing a stress","volume":"6","author":"Guettouche","year":"2005","journal-title":"BMC Biochem"},{"key":"2022061706334226500_bib33","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1038\/sj.onc.1201790","article-title":"Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol","volume":"16","author":"Sharma","year":"1998","journal-title":"Oncogene"},{"key":"2022061706334226500_bib34","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.exphem.2008.05.001","article-title":"The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors","volume":"36","author":"Lin","year":"2008","journal-title":"Exp Hematol"},{"key":"2022061706334226500_bib35","doi-asserted-by":"crossref","first-page":"8368","DOI":"10.1073\/pnas.0903392106","article-title":"Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models","volume":"106","author":"Caldas-Lopes","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022061706334226500_bib36","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","article-title":"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks","volume":"149","author":"Lee","year":"2012","journal-title":"Cell"},{"key":"2022061706334226500_bib37","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrd2614","article-title":"Nanoparticle therapeutics: an emerging treatment modality for cancer","volume":"7","author":"Davis","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"2022061706334226500_bib38","doi-asserted-by":"crossref","first-page":"5823","DOI":"10.1021\/acsnano.6b00320","article-title":"Rationally designed 2-in-1 nanoparticles can overcome adaptive resistance in cancer","volume":"10","author":"Goldman","year":"2016","journal-title":"ACS Nano"},{"key":"2022061706334226500_bib39","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4049\/jimmunol.167.3.1141","article-title":"Cutting edge: the mouse NK cell-associated antigen recognized by DX5 monoclonal antibody is CD49b (alpha 2 integrin, very late antigen-2)","volume":"167","author":"Arase","year":"2001","journal-title":"J Immunol"},{"key":"2022061706334226500_bib40","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/j.1365-2567.2008.03027.x","article-title":"CD56bright natural killer (NK) cells: an important NK cell subset","volume":"126","author":"Poli","year":"2009","journal-title":"Immunology"},{"key":"2022061706334226500_bib41","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200593","article-title":"Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells","volume":"190","author":"Bae","year":"2013","journal-title":"J Immunol"},{"key":"2022061706334226500_bib42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"key":"2022061706334226500_bib43","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer immunotherapy based on natural killer cells: current progress and new opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front Immunol"},{"key":"2022061706334226500_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.it.2018.12.003","article-title":"The emergence of natural killer cells as a major target in cancer immunotherapy","volume":"40","author":"Souza-Fonseca-Guimaraes","year":"2019","journal-title":"Trends Immunol"},{"key":"2022061706334226500_bib45","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00262-015-1761-x","article-title":"NK-92: an \u2018off-the-shelf therapeutic\u2019 for adoptive natural killer cell-based cancer immunotherapy","volume":"65","author":"Suck","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2022061706334226500_bib46","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.0105-2896.2010.00893.x","article-title":"Effect of NKG2D ligand expression on host immune responses","volume":"235","author":"Champsaur","year":"2010","journal-title":"Immunol Rev"},{"key":"2022061706334226500_bib47","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/23\/5355\/2800063\/5355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/80\/23\/5355\/2800063\/5355.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T15:39:34Z","timestamp":1655480374000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/80\/23\/5355\/646056\/Nanoengineered-Disruption-of-Heat-Shock-Protein-90"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":47,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020,12,2]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-19-4036","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.22426960","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426963","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426966","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426963.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426960.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512503.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22426966.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6512503","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,1]]}}}